Pharmaceutical benefit advisory committee acceptability threshold results 2005-2011

Research output: Contribution to journalLetterOther

Abstract

To examine the indicators of success in reimbursement application in Australia made by the Pharmaceutical Benefit Advisory Committee (PBAC), and describe the rationale behind it. Of interest is whether or not listing on the Pharmaceutical Benefit Scheme (PBS) is recommended based on the clinical evidence, the cost-effectiveness outcomes, political will, and whether there is clarity in the recommendations made for the subsidisation of drugs on the PBS. This examination is conducted in order to shed light on the basis of decision making and the impact of economic evaluations.
Original languageEnglish
Pages (from-to)622 - 622
Number of pages1
JournalValue in Health
Volume15
Issue number7
DOIs
Publication statusPublished - 2012

Cite this

@article{0e47ee46380a43f3ad28675a3ea79a73,
title = "Pharmaceutical benefit advisory committee acceptability threshold results 2005-2011",
abstract = "To examine the indicators of success in reimbursement application in Australia made by the Pharmaceutical Benefit Advisory Committee (PBAC), and describe the rationale behind it. Of interest is whether or not listing on the Pharmaceutical Benefit Scheme (PBS) is recommended based on the clinical evidence, the cost-effectiveness outcomes, political will, and whether there is clarity in the recommendations made for the subsidisation of drugs on the PBS. This examination is conducted in order to shed light on the basis of decision making and the impact of economic evaluations.",
author = "Kelly Makarounas-Kirchmann and Zanfani Ademi and M Kirchmann",
year = "2012",
doi = "10.1016/j.jval.2012.08.121",
language = "English",
volume = "15",
pages = "622 -- 622",
journal = "Value in Health",
issn = "1098-3015",
publisher = "Elsevier",
number = "7",

}

Pharmaceutical benefit advisory committee acceptability threshold results 2005-2011. / Makarounas-Kirchmann, Kelly; Ademi, Zanfani; Kirchmann, M.

In: Value in Health, Vol. 15, No. 7, 2012, p. 622 - 622.

Research output: Contribution to journalLetterOther

TY - JOUR

T1 - Pharmaceutical benefit advisory committee acceptability threshold results 2005-2011

AU - Makarounas-Kirchmann, Kelly

AU - Ademi, Zanfani

AU - Kirchmann, M

PY - 2012

Y1 - 2012

N2 - To examine the indicators of success in reimbursement application in Australia made by the Pharmaceutical Benefit Advisory Committee (PBAC), and describe the rationale behind it. Of interest is whether or not listing on the Pharmaceutical Benefit Scheme (PBS) is recommended based on the clinical evidence, the cost-effectiveness outcomes, political will, and whether there is clarity in the recommendations made for the subsidisation of drugs on the PBS. This examination is conducted in order to shed light on the basis of decision making and the impact of economic evaluations.

AB - To examine the indicators of success in reimbursement application in Australia made by the Pharmaceutical Benefit Advisory Committee (PBAC), and describe the rationale behind it. Of interest is whether or not listing on the Pharmaceutical Benefit Scheme (PBS) is recommended based on the clinical evidence, the cost-effectiveness outcomes, political will, and whether there is clarity in the recommendations made for the subsidisation of drugs on the PBS. This examination is conducted in order to shed light on the basis of decision making and the impact of economic evaluations.

U2 - 10.1016/j.jval.2012.08.121

DO - 10.1016/j.jval.2012.08.121

M3 - Letter

VL - 15

SP - 622

EP - 622

JO - Value in Health

JF - Value in Health

SN - 1098-3015

IS - 7

ER -